Search research articles
Contact Us
Filters
Showing results (131-140 of 383) with videos related to
Page
of 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
Vicki A Morrison, Kanti R Rai, Bercedis L Peterson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 15, 2011
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation
Koen van Besien, Wendy Stock, Elizabeth Rich, et al.
Blood
|
May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
John C Byrd, Kanti Rai, Bercedis L Peterson, et al.
Leukemia & Lymphoma
|
February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Leukemia & Lymphoma
|
August 3, 2018
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation
Christopher R D'Angelo, Brianna Novitsky, Sang Mee Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2005
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
John C Byrd, John G Gribben, Bercedis L Peterson, et al.
British Journal of Haematology
|
May 3, 2020
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib
Anand A Patel, Kirk Cahill, Angella Charnot-Katsikas, et al.
Leukemia Research
|
May 27, 2005
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity
Ian W Flinn, John C Byrd, Nancy Bartlett, et al.
Annals of Translational Medicine
|
June 24, 2024
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in <i>FLT3</i>-mutated acute myeloid leukemia (AML) patients
Gong He, Erika Belmont, Theodore Karrison, et al.
Investigational New Drugs
|
May 24, 2013
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
Pankaj Gupta, Flora Mulkey, Robert P Hasserjian, et al.
Page
of 39
Search research articles
Search
Showing results (131-140 of 383) with videos related to
Sort By:
Page
of 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
Vicki A Morrison, Kanti R Rai, Bercedis L Peterson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 15, 2011
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation
Koen van Besien, Wendy Stock, Elizabeth Rich, et al.
Blood
|
May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
John C Byrd, Kanti Rai, Bercedis L Peterson, et al.
Leukemia & Lymphoma
|
February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Leukemia & Lymphoma
|
August 3, 2018
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation
Christopher R D'Angelo, Brianna Novitsky, Sang Mee Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2005
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
John C Byrd, John G Gribben, Bercedis L Peterson, et al.
British Journal of Haematology
|
May 3, 2020
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib
Anand A Patel, Kirk Cahill, Angella Charnot-Katsikas, et al.
Leukemia Research
|
May 27, 2005
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity
Ian W Flinn, John C Byrd, Nancy Bartlett, et al.
Annals of Translational Medicine
|
June 24, 2024
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in <i>FLT3</i>-mutated acute myeloid leukemia (AML) patients
Gong He, Erika Belmont, Theodore Karrison, et al.
Investigational New Drugs
|
May 24, 2013
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
Pankaj Gupta, Flora Mulkey, Robert P Hasserjian, et al.
Page
of 39